RBI-3000 / Replicate Biosci - LARVOL DELTA

Self-replicating RNA therapeutics for off-the-shelf precision immunotherapy targeting acquired resistance mutations in low TMB tumors (SITC 2023) - "mRNA-4157 is a personalized neoantigen vaccine (Moderna) that, when combined with pembrolizumab, demonstrated prolongation of RFS and DMFS when given as adjuvant therapy for high-risk melanoma following complete resection...Results Replicate Bioscience has developed a precision immunotherapy (PIO), RBI-1000, targeting ARM in ER+ breast cancer...RBI-3000, our EGFRm PIO and second oncology therapeutic, targets the known resistance mutations, and primary mutations that are less responsive to tyrosine kinase inhibitor (TKI) therapy and will be administered in combination with SOC TKIs. The coupling of targeted and PIO therapies is anticipated to better address clinical need in the metastatic setting, with chemotherapy replacing surgical resection to address tumor bulk. Conclusions PIO is a novel approach to cancer immunotherapy that is widely applicable to any cancer with characterized ARM."

IO biomarker • Preclinical • Breast Cancer • Hormone Receptor Breast Cancer • Melanoma • Oncology • Solid Tumor • ER • TMB

Replicate Bioscience to Present Progress on Two srRNA Oncology Programs at Society for Immunotherapy of Cancer 2023 Meeting (PRNewswire) - "Poster presentation describes potential of oncology programs RBI-1000 and RBI-3000 to target known acquired resistance mutations....RBI-1000 leads to tumor control with the elimination of tumor cells expressing ARM in preclinical models....RBI-3000 is an srRNA PIO program targeting acquired resistance to current tyrosine kinase inhibitor standard of care therapy for metastatic EGFRm+ non-small cell lung cancer."

Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor